Evidence map›Paper›PMID 35746491›Full record

ArticleVaccines2022

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.

Helen R Wagstaffe, Omu Anzala, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B Sirima, Rodolphe Thiébaut, Laura Richert, Yves Levy, Christine Lacabaratz, Viki Bockstal and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 8 countries.

Helen R WagstaffeDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.ORCID 0000-0002-4462-7484
Omu AnzalaKAVI-Institute of Clinical Research University of Nairobi, Nairobi 19676, Kenya.
Hannah KibuukaMakerere University-Walter Reed Project, Kampala 16524, Uganda.
Zacchaeus AnywaineMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda.
Sodiomon B SirimaCentre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, 1487 Avenue Kumda Yonré, Ouagadougou 01 BP 2208, Burkina Faso.ORCID 0000-0002-0972-4211
Rodolphe ThiébautBordeaux Population Health Research Center, University Bordeaux, Inserm, UMR 1219, 33000 Bordeaux, France.
Laura RichertBordeaux Population Health Research Center, University Bordeaux, Inserm, UMR 1219, 33000 Bordeaux, France.
Yves LevyInserm U955, Vaccine Research Institute, Université Paris-Est Créteil, Hôpital Henri Mondor, 94010 Creteil, France.
Christine LacabaratzInserm U955, Vaccine Research Institute, Université Paris-Est Créteil, Hôpital Henri Mondor, 94010 Creteil, France.ORCID 0000-0001-6925-0225
Viki BockstalJanssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands.
Kerstin LuhnJanssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands.
Macaya DouoguihJanssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands.
Martin R GoodierDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.ORCID 0000-0002-8963-4768
Janssen (Netherlands) · NLInserm · FRInstitut national de recherche en sciences et technologies du numérique · FRUniversity of London · GBCentre National de Recherche et de Formation sur le Paludisme · BFMakerere University Walter Reed Project · UGMedical Research Council · GBUniversity of Nairobi · KE

Funding

Innovative Medicines Initiative 115861
6 · The paper itself

Abstract

Natural killer cells play an important role in the control of viral infections both by regulating acquired immune responses and as potent innate or antibody-mediated cytotoxic effector cells. NK cells have been implicated in control of Ebola virus infections and our previous studies in European trial participants have demonstrated durable activation, proliferation and antibody-dependent NK cell activation after heterologous two-dose Ebola vaccination with adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo. Regional variation in immunity and environmental exposure to pathogens, in particular human cytomegalovirus, have profound impacts on NK cell functional capacity. We therefore assessed the NK cell phenotype and function in African trial participants with universal exposure to HCMV. We demonstrate a significant redistribution of NK cell subsets after vaccine dose two, involving the enrichment of less differentiated CD56

Indexed as

AfricaantibodyEbolanatural killer cellvaccine

Identifiers

PMID35746491
PMCPMC9230153
OpenAlexW4281892533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.